The CentraSight treatment program uses an implantable medical device - the Implantable Miniature Telescope (by Dr. Isaac Lipshitz) - which is indicated for monocular implant to improve vision in patients with stable severe to profound vision impairment caused by bilateral central scotomas (blind areas) associated with end-stage age-related macular degeneration.
Patients must meet age, vision, cornea health, and other requirements noted in the Patient Information Booklet.
The most common risks of the telescope implantation surgery include inflammatory deposits or precipitates on the device and increased intraocular pressure. Significant adverse events include corneal edema, corneal decompensation, corneal transplant, and decrease in visual acuity. There is a risk that having the telescope implantation surgery could worsen your vision rather than improve it. Individual results may vary.